Comment on “Protection from COVID-19 vaccination and prior SARS-CoV-2 infection among children aged 6 months - 4 years...”

In the United States, mRNA COVID-19 vaccines were first authorized in June 2022 for childrenaged 6 months - 4 years with the aim to prevent severe outcomes from COVID-19. However, dataon the actual safety and efficacy to prevent infection or severe disease, also in the context of priorexposure to the virus and the emergence of new viral variants, are scarce. To address this extremelyurgent issue, Feldstein et al. [4] recently published merged data from 3 prospective cohort studies inchildren <5 years of age. The information provides valuable insights into the real-world performanceof the injections in this age group. In contrast to the author’s highlights of their potential to reducesevere disease, here, an independent analysis that examines the totality of data, identifies importantinsights missed before. The critique done here is exclusively based on the information provided in [4]and identifies the radically opposing narrative given by Feldstein et al., in sharp contradiction to theirown findings. This investigation concludes with potential underlying mechanisms to explain some ofthe underappreciated data by Feldstein and collaborators.